These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Weekly intramuscular methotrexate in the treatment of low-risk gestational trophoblastic neoplasia.
    Author: Mohit M, Sarraf Z, Sheikhi G, Robati M, Vasheghani-Farahani A.
    Journal: Arch Gynecol Obstet; 2009 Nov; 280(5):775-80. PubMed ID: 19263063.
    Abstract:
    OBJECTIVE: The objective of this study was to determine the efficacy of weekly intramuscular (IM) methotrexate without dose escalation as first-line chemotherapy for low-risk gestational trophoblastic neoplasia (LRGTN). METHODS: Thirty-three women with post-molar LRGTN in the division of gynecology oncology at the Shiraz University of Medical Sciences were treated with weekly IM methotrexate at 30 mg/m(2) without dose escalation. The serum level of beta-hCG was detected every week. After the first negative beta-hCG level, one more cycle was administered as consolidation. Complete response (CR) was defined as the attainment of serum beta-hCG level of 5 IU/L or less measured on three consecutive weeks. RESULTS: Twenty-one of 33 women (63.6%) achieved CR with weekly IM injection of 30 mg/m(2) methotrexate. Ten of 12 patients with weekly IM methotrexate failure had a CR after one to three courses of dactinomycin administered at 1.25 mg/m(2) intravenously every 2 weeks. Two patients needed multiple-agent chemotherapy for remission. CONCLUSIONS: Weekly methotrexate without dose escalation may be an appropriate option for primary chemotherapy of patients with LRGTN.
    [Abstract] [Full Text] [Related] [New Search]